Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Institut De Recherches Internationales Servier IRIS

Conditions

BRAF and Other Selected RAS/MAPK MutationsMalignancies with Documented KRASadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionswho failed prior line of palliative chemotherpay

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISBRAF and Other Selected RAS/MAPK Mutations, Malignancies with Documented KRAS

Target: 75Updated: 2026-04-22

Phase 3

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY

Active, not recruitingCTIS2024-512934-14-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

Start: 2016-11-07Target: 319Updated: 2025-06-23